A Study of Dideoxycytidine in HIV-Infected Patients
Information source: National Institute of Allergy and Infectious Diseases (NIAID)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: Zalcitabine (Drug)
Phase: N/A
Status: Completed
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID) Official(s) and/or principal investigator(s):
Lietman P, Study Chair
Summary
To determine how much of a dose is absorbed by the body when zalcitabine ( dideoxycytidine;
ddC ) is given orally and how long the drug stays in the body after absorption or intravenous
(IV) administration.
Laboratory tests have shown that ddC is effective in stopping the growth of the HIV in test
tubes. The study will reveal the pharmacokinetic (blood levels) properties of this new drug
and how long the drug remains in the body at each of six doses. This should be useful
background information and should allow a simple and efficient comparative study of any new
oral formulation, such as a tablet or capsule, since dose-related problems will already be
known.
Clinical Details
Official title: Pharmacokinetics and Bioavailability of Dideoxycytidine in Patients With Human Immunodeficiency Virus Infection
Study design: Treatment, Open Label, Pharmacokinetics Study
Detailed description:
Laboratory tests have shown that ddC is effective in stopping the growth of the HIV in test
tubes. The study will reveal the pharmacokinetic (blood levels) properties of this new drug
and how long the drug remains in the body at each of six doses. This should be useful
background information and should allow a simple and efficient comparative study of any new
oral formulation, such as a tablet or capsule, since dose-related problems will already be
known.
Patients are hospitalized and receive ddC twice, once by mouth and once by IV injection. Each
patient receives the drug at one of six increasing doses, and no patient is studied at more
than one dose level. Following each dose, toxicity is measured before the next higher dose is
given. Several blood samples and urine specimens are taken to permit measurement of the
amount of drug in the bloodstream and of the speed with which it is eliminated from the
body.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria
Prior Medication:
Allowed:
- Oral nonabsorbable antifungal agents.
Exclusion Criteria
- Active drug or alcohol abuse.
Co-existing Condition:
- Patients with fever > 102 degrees F at study entry will be excluded.
- Patients with fever > 102 degrees F at study entry will be excluded.
Prior Medication: Excluded:
- Chronic systemic medications.
- Any other experimental drug within 2 weeks of study entry.
- Drugs with known nephrotoxic or hepatotoxic effects within 2 weeks of study entry.
- Drugs known to cause neutropenia within 2 weeks of study entry.
- Rifampin or rifampin derivatives, phenytoin, or barbiturates within 2 weeks of study
entry.
- Any other medication except oral nonabsorbable antifungal agents within 72 hours of
study entry.
All medications, including aspirin, must be approved by investigator. All medications,
including aspirin, must be approved by investigator.
Patients must demonstrate the following clinical and laboratory findings:
- AIDS, AIDS related complex (ARC), or persistent generalized lymphadenopathy as defined
by the CDC classification.
- No ascites.
- Off all medications except oral antifungal, nonabsorbable agents for 72 hours prior to
study entry.
Locations and Contacts
Johns Hopkins Hosp, Baltimore, Maryland 21287, United States
Additional Information
Click here for more information about Zalcitabine
Related publications: Gustavson LE, Fukuda EK, Rubio FA, Dunton AW. A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex. J Acquir Immune Defic Syndr. 1990;3(1):28-31.
Last updated: June 23, 2005
|
